Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 22 September

Sam Kanaan
September 22, 2023

Morning Bell 21 September

Sophia Mavridis
September 21, 2023

Morning Bell 20 September

Sam Kanaan
September 20, 2023

Morning Bell 19 September

Sophia Mavridis
September 19, 2023

Morning Bell 18 September

Sam Kanaan
September 18, 2023

Weekly Wrap 15 September

Grady Wulff
September 15, 2023

Morning Bell 15 September

Sam Kanaan
September 15, 2023

Morning Bell 14 September

Grady Wulff
September 14, 2023

Morning Bell 13 September

Grady Wulff
September 13, 2023

Morning Bell 12 September

Sam Kanaan
September 12, 2023

Morning Bell 11 September

Grady Wulff
September 11, 2023

Weekly Wrap 8 September

Grady Wulff
September 8, 2023